Pharma IQ | 10/27/2014
As biotech/emerging companies develop and their assets/operations approach commercial maturity we see a change in the skill mix sought by Chairs.
o It is unsurprising that 70% of those surveyed say that knowledge of the Life Sciences industry is essential.
o In recent years it has become apparent to us that commercialisation experience is a crucial part of the skill mix for a Life Sciences Board- 58% of our survey agrees.
o As open Innovation rises and in-house generated pipelines con...
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
GenAI Life Science & Health 2025
September 1 - 3 2025
Berlin, Germany
Register Now |
View Agenda |
Learn More
DigIT Pharma AI Commercial Excellence & Health 2025
September 1 - 3 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More